PE20030043A1 - Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo - Google Patents

Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo

Info

Publication number
PE20030043A1
PE20030043A1 PE2002000455A PE2002000455A PE20030043A1 PE 20030043 A1 PE20030043 A1 PE 20030043A1 PE 2002000455 A PE2002000455 A PE 2002000455A PE 2002000455 A PE2002000455 A PE 2002000455A PE 20030043 A1 PE20030043 A1 PE 20030043A1
Authority
PE
Peru
Prior art keywords
alkyl
activator
peroxisome
proliferator
azol
Prior art date
Application number
PE2002000455A
Other languages
English (en)
Inventor
Peter T Cheng
Hao Zhang
Narayanan Hariharan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20030043A1 publication Critical patent/PE20030043A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A DERIVADOS ACIDOS DE AZOL DE FORMULA I DONDE m Y n SON 0-2; Q ES C, N; A ES (CH2)x, (CH2)x1, (CH2)x2-O-(CH2)x3; x ES 1-5; x1 ES 2-5; x2 Y x3 SON 0-5; UNO DE x2 Y x3 ES DIFERENTE DE CERO; X1 ES CH, N; X2, X3, X4, X5, X7 SON C, N, O, S; UNO DE X2-X4 O X5-X7 ES N; X6 ES C, N; R1 ES H, ALQUILO; R2, R2a, R2b, R2c SON H, ALQUILO, ALCOXI, HALOGENO, AMINO; R3 Y R3a SON H, ALQUILO, ARILALQUILO, ARILOXICARBONILO, ALQUILOXICARBONILO, ENTRE OTROS, Y ES CO2R4, 1-TETRAZOL, PO(OR4a)R5, PO(OR4a)2; R4 ES H, ALQUILO O UN ESTER DE PROFARMACO, R4a ES H, ESTER DE PROFARMACO; R5 ES ALQUILO, ARILO; (CH2)x, (CH2)x1, (CH2)x2, (CH2)x3, (CH2)m, (CH2)n OPCIONALMENTE SUSTITUIDOS CON 1 A 3 SUSTITUYENTES. TAMBIEN SE REFIERE A UNA COMBINACION QUE COMPRENDE UN AGENTE QUE DISMINUYE LOS LIPIDOS Y UN AGENTE ANTIDIABETICO TAL COMO METFORMINA, GLIBURIDA, GLIMEPIRIDA, GLIPIRIDA, GLIPIZIDA, CLORPROPAMIDA, GLICLAZIDA, IRBESARTAN, LOSARTAN, VALSARTAN, AMLODIPINO, ENTRE OTROS. LOS COMPUESTOS TIENEN ACTIVIDAD DUAL SON ANTAGONISTAS DEL RECEPTOR g ACTIVADOR DEL PROLIFERADOR DE PEROXISOMA Y AGONISTAS DEL RECEPTOR a ACTIVADOR PROLIFERADOR DE PEROXISOMA POR LO QUE MODULAN LOS NIVELES DE GLUCOSA, TRIGLICERIDOS, INSULINA, ACIDOS GRASOS NO ESTERIFICADOS EN SANGRE Y PUEDEN SER UTILES PARA TRATAR DIABETES, ENFERMEDAD CARDIOVASCULAR, TUMOR EPITELIAL, LIPOSARCOMA, TUMOR EPITELIAL; ADEMAS LOS COMPUESTOS ALTERAN LA EXPRESION DE HMGic, GLICEROL-P04 DESHIDROGENASA, PROTEINA DE TRANSPORTE DE ACIDOS GRASOS, ENTRE OTROS
PE2002000455A 2001-05-30 2002-05-30 Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo PE20030043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29438001P 2001-05-30 2001-05-30

Publications (1)

Publication Number Publication Date
PE20030043A1 true PE20030043A1 (es) 2003-02-05

Family

ID=23133159

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000455A PE20030043A1 (es) 2001-05-30 2002-05-30 Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo

Country Status (17)

Country Link
US (1) US20030092736A1 (es)
EP (1) EP1390363A4 (es)
JP (1) JP2004536070A (es)
AU (1) AU2002259306B2 (es)
CA (1) CA2449160A1 (es)
CZ (1) CZ20033230A3 (es)
DE (1) DE02729306T1 (es)
ES (1) ES2214168T1 (es)
HU (1) HUP0401504A3 (es)
MX (1) MXPA03010997A (es)
NO (1) NO327089B1 (es)
PE (1) PE20030043A1 (es)
PL (1) PL367066A1 (es)
TR (1) TR200400650T3 (es)
TW (1) TWI235061B (es)
UY (1) UY27316A1 (es)
WO (1) WO2002096358A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017896A2 (en) * 2002-08-21 2004-03-04 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2004108126A1 (en) * 2003-06-06 2004-12-16 Snowden Pharmaceuticals, Llc Fibric acid derivatives for the treatment of irritable bowel syndrome
WO2005005421A1 (en) * 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
BRPI0414580A (pt) * 2003-09-22 2006-11-07 Ono Pharmaceutical Co derivado do ácido fenilacético, processos para sua produção e uso
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CN1304393C (zh) * 2004-07-01 2007-03-14 中国药科大学 取代的吡唑啉酮衍生物及其制备方法与药用组合物
WO2006057503A1 (en) * 2004-11-25 2006-06-01 Lg Life Sciences, Ltd. NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
KR100706600B1 (ko) * 2004-11-25 2007-04-12 주식회사 엘지생명과학 ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물
WO2007058504A1 (en) * 2005-11-21 2007-05-24 Lg Life Sciences, Ltd. Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same
WO2008127813A1 (en) * 2007-03-09 2008-10-23 Hiberna Corporation Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use
WO2009073564A1 (en) * 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
BRPI0920765A2 (pt) * 2008-10-29 2015-08-18 Deciphera Pharmaceuticals Llc Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN109498622A (zh) * 2018-12-28 2019-03-22 成都恒瑞制药有限公司 一种氯沙坦钾与罗格列酮组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
CZ20013834A3 (cs) * 1999-04-28 2002-04-17 Aventis Pharma Deutschland Gmbh Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
WO2001017994A1 (en) * 1999-09-08 2001-03-15 Glaxo Group Limited Oxazole ppar antagonists
PT1228067E (pt) * 1999-11-10 2004-11-30 Takeda Chemical Industries Ltd Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica
EP1394154A4 (en) * 2001-03-23 2005-05-18 Takeda Pharmaceutical HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID

Also Published As

Publication number Publication date
UY27316A1 (es) 2002-12-31
WO2002096358A3 (en) 2003-03-27
EP1390363A2 (en) 2004-02-25
MXPA03010997A (es) 2004-02-27
TR200400650T3 (tr) 2004-06-21
NO20035312D0 (no) 2003-11-28
CZ20033230A3 (cs) 2004-02-18
JP2004536070A (ja) 2004-12-02
HUP0401504A2 (hu) 2004-11-29
AU2002259306B2 (en) 2007-02-08
HUP0401504A3 (en) 2008-05-28
CA2449160A1 (en) 2002-12-05
US20030092736A1 (en) 2003-05-15
PL367066A1 (en) 2005-02-21
EP1390363A4 (en) 2011-01-05
DE02729306T1 (de) 2004-08-26
TWI235061B (en) 2005-07-01
ES2214168T1 (es) 2004-09-16
NO327089B1 (no) 2009-04-20
WO2002096358A2 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
PE20030043A1 (es) Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
ES2526463T3 (es) Exendina para el tratamiento de la diabetes y la reducción del peso corporal
EA200500080A1 (ru) Дозированная форма прамипексола, принимаемая один раз в день
PE20011056A1 (es) Acidos ariloxiaceticos para la diabetes y trastornos de los lipidos
ES2216513T3 (es) Nuevos analogos heterociclicos de compuestos de difeniletileno.
JP2004536115A5 (es)
AR015358A1 (es) Antagonistas de la endotelina: n-[[2'-[[(4,5-dimetil-3-isoxazolil)amino]sulfonil]-4-(2-oxazolil)[1,1'-bifenil]-2-il]metil]-n,3,3-trimetilbutanamida yn-(4,5-demitil-3-isoxazolil)-2'-[(3,3-dimetil-2-oxo-1-pirrolidinil)metil]-4'-(2-oxazolil)[1,1'-bifenil]-2-sulfonamida y sales de los mismos y las compo
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
CO6150170A2 (es) Derivados de 1-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
PE20040655A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen
WO2001012187A3 (en) Benzoic acid derivatives and their use as ppar receptor agonists
RU2005141226A (ru) Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
PA8562801A1 (es) Nuevos derivados de pirido (2,1-a) isoquinolina
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
PE20030989A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
ES2137260T3 (es) Composicion farmaceutica para uso en el tratamiento del glaucoma.
RU2007139928A (ru) Производное бензимидазола и применение в качестве антагониста ангиотензина
PE20061446A1 (es) Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
PE20080834A1 (es) Derivados de eter diarilico antagonistas de receptores opioides
AR029005A1 (es) FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA
NO890529D0 (no) Oksazolidin-2-on-derivater som hypoglycemiske midler.

Legal Events

Date Code Title Description
FD Application declared void or lapsed